Injection of Bromelain and Acetylcysteine in Combination Into Recurrent Mucinous Tumour or Pseudomyxoma Peritonei
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03976973|
Recruitment Status : Not yet recruiting
First Posted : June 6, 2019
Last Update Posted : August 14, 2019
This study involves 60 patients with mucinous peritoneal tumour, including pseudomyxoma peritonei (PMP), that are not suitable for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) or other potentially beneficial surgery.
The combination drug treatment of Bromelain and Acetylcysteine will be injected directly into the tumour or peritoneal cavity via a drain and allowed to dwell for 24 hours. The tumour will then be drained and a repeat treatment will be considered.
An interventional radiologist will insert a percutaneous drain. The drain will remain in situ for the treatment period. The aspiration/drainage and repeat drug treatments will be delivered via this drain. The dose of the drug is dependent on the calculated tumour dimensions and volume outlined in the protocol.
The expectation is that the drug combination will dissolve the tumour, allowing it to be drained. Remaining mucinous tumour that is unable to be drained will be considered for repeat drug treatments.
|Condition or disease||Intervention/treatment||Phase|
|Pseudomyxoma Peritonei Peritoneal Cancer Mucinous Adenocarcinoma Mucinous Tumor||Drug: Bromelain, Stem Drug: Acetylcysteine Procedure: Interventional radiology insertion of drain Diagnostic Test: Pathology: blood testing during intervention Other: Routine follow up||Phase 1 Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Injection of Bromelain and Acetylcysteine in Combination Into Recurrent Mucinous Tumour or Pseudomyxoma Peritonei|
|Estimated Study Start Date :||November 2019|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||March 2021|
Patients with inoperable pseudomyxoma peritonei or peritoneal mucinous tumour that meet the entry criteria and consent to the intervention will have intratumoural or intraperitoneal treatment/s with Bromelain and Acetylcysteine. The drug combination will be injected directly into the tumour or free intraperitoneally via a percutaneously radiologically placed catheter.
Drug: Bromelain, Stem
An intratumoural injection of Bromelain 30-45mg or an intraperitoneal injection of Bromelain 60mg will be administered via a radiologically drain in combination with Acetylcysteine in 5% glucose.
Other Name: Bromelain
An intratumoural injection of Acetylcysteine 1.5mg or an intraperitoneal injection of Acetylcysteine 2g will be administered via a radiologically drain in combination with Bromelain in 5% glucose.
Procedure: Interventional radiology insertion of drain
Under radiological guidance (CT), a needle, wire, dilator will be placed directly into the tumour then a large pigtail drain (i.e. 10Fg) will be placed into the tumour by an experienced, interventional radiologist, under standard procedures.
Diagnostic Test: Pathology: blood testing during intervention
Blood tests are taken 3 hours after each drug intervention then 24 hours following the last drug intervention to assess for short-term systemic side effects and measure pharmacokinetics of bromelain and acetylcysteine.
Other: Routine follow up
Patients will have outpatient reviews at 1 week and 1, 3, 6, 9 and 12 months post drug intervention. Blood tests will be performed at 1 week and 1, 3, 6, 9 and 12 months after the drug intervention to assess for short and long term systemic side effects. At 1, 3, 6, 9 and 12 months post drug intervention, a CT-scan is part of the study protocol to assess for response and progression of disease.
- Tumour response [ Time Frame: 1 month ]Tumour changes following Bromelain and NAC combination treatment. Efficacy will be measured by the volume of fluid aspirated from the drain (dissolved tumour). The treatment will be seen effective if >25% of tumour volume is aspirated or there is a >20% reduction in dimensions on CT scan post treatment at 1 month compared to the pre-treatment scan.
- Incidence of Treatment-Emergent Adverse Events (Pathology) [Safety and Tolerability] [ Time Frame: 1 month ]Reported as any untoward medical occurrence or worsening of a pre-existing medical condition in a participant administered bromelain and NAC, and judged possibly, probably, or definitely related to treatment
- Progression free survival post treatment [ Time Frame: 1, 3, 6, 9 and 12 months ]Time to progression of the treated area based on repeat CT scanning where RECIST v1.1 will be used where possible. The follow up scan will be compared to the 1 month post treatment scan where dimensions and volume will be calculated by an experienced radiologist.
- Quality of life score and impact of treatment on quality of life in palliative cancer patients [ Time Frame: Baseline, then at 1 month, 3 months, 9 months and 12 months ]Standardised quality of life (QLQ) questionnaire European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire EORTC QLQ-C15-PAL for quality of life measurement in palliative cancer patients. Does the treatment with BrNAC improve quality of life? Scale range is 1 to 4; 1 (not at all) being no improvement in quality of life to the maximal rating of 4 (improvement in quality of life).
- Impact of treatment on Quality of Life in colorectal type diseases - assess the most accurate trend of the Global Health Status (Quality of Life evolution) over time in mucinous cancer patients evaluated by the EORTC-QLQ-C30 questionnaire. [ Time Frame: Baseline, then at 1 month, 3 months, 9 months and 12 months ]
The EORTC-QLQ-C30 (European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire - C30) is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / Quality of Life (QoL) scale, and six single items.
The global health status / Quality of Life scale runs from 1 (very poor) to 7 (excellent) and the others from 1 (not at all) to 4 (very much). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus:
a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
- Impact of treatment on Quality of Life in colorectal type diseases - assess the trend of over time in mucinous cancer (colorectal type) patients by the European Organisation for Research and Treatment of Cancer (EORTC) EORTC-QLQ-CR29 questionnaire [ Time Frame: Baseline, then at 1 month, 3 months, 9 months and 12 months ]The symptom scores (Fatigue, Nausea and vomiting, Pain …), running from 1 (not at all) to 4 (very much), will be evaluated by the use of the European Organisation for Research and Treatment of Cancer EORTC-QLQ-CR29 questionnaire. The trend of each category of PROMS given by the EORTC-QLQ-CR29 in four groups of patients: tumour on the right and transverse part of the colon; tumour on the left part of the colon; rectal tumour; metastatic colorectal cancer.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03976973
|Contact: David L Morris, MD, PhDfirstname.lastname@example.org|
|Contact: Sarah J Valle, BNemail@example.com|
|Principal Investigator:||David L Morris, MD, PhD||St George Hospital|